# US 2025/0052757 A1 · Use of PD-L1 Low Expression Status to Select Subjects for Cancer Immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0052757 A1
- Document ID: US20250052757A1
- Status: Published application
- Kind: A1
- Application number: 18/799,733
- Filed: 2024-08-09
- Published: 2025-02-13
- Earliest claimed: 2023-08-10
- Applicants: Vaccinex, Inc.; MSD International GmbH
- Inventors: Elizabeth EVANS; Maurice ZAUDERER; Terry FISHER
- Web page: https://patentgrep.com/patent/US20250052757A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2474/20: Immunohistochemistry assay
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.

## Claims

### Claim 1

A method of selecting subjects having or suspected of having cancer for treatment with an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of at least one other immune modulating therapy, preferably at least one immune checkpoint inhibitor, which comprises
(a) determining PD-L1 expression levels in tumor tissue or cancerous cells of a subject; and
(b) selecting the subject for treatment if
(i) the tumor tissue is identified as having a combined positive score (CPS) of <25 or a tumor proportion score (TPS) ranging from <50% to <80% for PD-L1 expression, or
(ii) the cancerous cells are identified as having a TPS ranging from <50% to <80% for PD-L1 expression.

### Claim 2

A method for treating, inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising:
(a) determining PD-L1 expression levels in tumor tissue or cancerous cells of the subject; and
(b) administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of at least one other immune modulating therapy, preferably at least one immune checkpoint inhibitor, if the tumor tissue or cells are identified as having either or both of a combined positive score (CPS) of <25 for PD-L1 expression or a tumor proportion score (TPS) ranging from <50% to <80%, thereby treating the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein PD-L1 expression levels are determined by immunohistochemical analysis.

### Claim 4 (depends on 3)

The method of claim 3 wherein said anti-SEMA4D antibody or antigen-binding fragment thereof inhibits SEMA4D interaction with its receptor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the receptor is Plexin-B1, Plexin-B2, CD72, or any combination thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the antibody or fragment thereof inhibits SEMA4D-mediated signal transduction.

### Claim 7 (depends on 4)

The method of claim 4, wherein said anti-SEMA4D antibody or antigen-binding fragment thereof is selected from the group consisting of
(i) an antibody or antigen binding fragment thereof comprising a variable heavy chain (VH) region having VH CDRs 1-3 comprising amino acid sequences SEQ ID NOS:1, 2, and 3, respectively, and a variable light chain (VL) region comprising VL CDRs 1-3 comprising SEQ ID NOS:4, 5, and 6, respectively;
(ii) the antibody of (i), or antigen binding fragment thereof, wherein the VH and VL chains comprise, respectively, SEQ ID NO:7 and SEQ ID NO:8 (human), or SEQ ID NO:9 and SEQ ID NO:10 (mouse);
(iii) an antibody or antigen binding fragment thereof comprising a VH region having VH CDRs 1-3 comprising amino acid sequences SEQ ID NOS:11, 12, and 13, respectively; and a VL region comprising VL CDRs 1-3 comprising amino acid sequences SEQ ID NOS:14, 15, and 16, respectively; and
(iv) the antibody of (ii), or antigen binding fragment thereof, wherein the VH and VL chains comprise, respectively, SEQ ID NO:17 and SEQ ID NO:18.

### Claim 8 (depends on 1)

The method of claim 1, wherein the at least one immune checkpoint inhibitor is an anti-CTLA4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-LAG3 antibody, an anti-TIGIT antibody, an anti-B7-H3 antibody or a combination thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the anti-PD-1 antibody is pembrolizumab, cemiplimab, dostarlimab or nivolumab, and preferably is pembrolizumab.

### Claim 10 (depends on 2)

The method of claim 2, wherein the isolated antibody or antigen-binding fragment thereof and the at least one other immune modulating therapy, preferably the at least one immune checkpoint inhibitor, are administered separately or concurrently.

### Claim 11 (depends on 2)

The method of claim 2, wherein administration of the combination of the isolated antibody or antigen-binding fragment thereof and the at least one other immune modulating therapy, preferably the at least one immune checkpoint inhibitor, results in enhanced therapeutic efficacy relative to administration of the at least one other immune modulating therapy, preferably the at least one immune checkpoint inhibitor, alone, wherein such enhancement is an approximately two-fold improvement in the objective response rate (ORR).

### Claim 12 (depends on 2)

The method of claim 2, am which further comprise administering an immune modulating therapy, radiation or chemotherapy.

### Claim 13 (depends on 12)

The method of claim 12, wherein the immune modulating therapy is selected from the group consisting of administration of a cancer vaccine, administration of an immunostimulatory agent, adoptive T cell or antibody therapy, administration of an immune checkpoint inhibitor, administration of a regulatory T cell (Treg) modulator, and a combination thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the immune modulating therapy comprises a second immune checkpoint inhibitor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the second immune checkpoint inhibitor is selected from the group consisting of an antibody or antigen-binding fragment thereof that specifically binds to CTLA4, PD-1, PD-L1, LAG3, TIM3, B7-H3, TIGIT or any combination thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the antibody or antigen-binding fragment of the second immune checkpoint inhibitor comprises the anti-PD-L1 antibody avelumab, atezolizumab, durvalumab.

### Claim 17 (depends on 13)

The method of claim 13, wherein the immune modulating therapy comprises administration of a cancer vaccine.

### Claim 18 (depends on 13)

The method of claim 13, wherein the Treg modulator is cyclophosphamide

### Claim 19 (depends on 1)

The method of claim 1, wherein the cancer is carcinoma, lymphoma, blastoma, sarcoma, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, esophageal cancer, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, head and neck cancer, or any combination thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of locally advanced or recurrent or metastatic (in all of the following) head and neck cancer, non-small cell lung cancer, cervical cancer, urothelial carcinoma, esophogeal squamous cell carcinoma (ESCC), renal cell carcinoma, ovarian cancer, prostate cancer, bladder cancer, pancreatic cancer, gastrointestinal cancer, hepatocellular carcinoma, sarcoma, melanoma, triple negative breast cancer (TNBC), microsatellite instability/mismatch repair (MSI/MMR) deficient tumors and colorectal cancer.

### Claim 21

A method of treating cancer in a human patient identified as having a tumor with low PD-L1 expression which comprises administering to the patient, as combination immunotherapy,
(a) an anti-semaphorin-4D (SEMA4D) antibody, or an antigen binding fragment thereof, and
(b) an immune checkpoint inhibitor,
wherein the tumor has a combined positive score (CPS) of <25 before the immune checkpoint inhibitor is administered.

### Claim 22 (depends on 21)

The method of claim 21, wherein CPS is <20 or CPS is <10.

### Claim 23 (depends on 21)

The method of claim 21, wherein said immune checkpoint inhibitor is an anti-PD-1 antibody, preferably pembrolizumab.

### Claim 24 (depends on 21)

The method of claim 21, wherein said anti-SEMA4D antibody is pepinemab.

### Claim 25 (depends on 21)

The method of claim 21, wherein said cancer is selected from the group consisting of locally advanced or recurrent or metastatic (in all of the following) head and neck cancer, non-small cell lung cancer, cervical cancer, urothelial carcinoma, esophogeal squamous cell carcinoma (ESCC), renal cell carcinoma, ovarian cancer, prostate cancer, bladder cancer, pancreatic cancer, gastrointestinal cancer, hepatocellular carcinoma, sarcoma, melanoma, triple negative breast cancer (TNBC), microsatellite instability/mismatch repair (MSI/MMR) deficient tumors and colorectal cancer.

### Claim 26

A method of treating cancer in a human patient identified as having a tumor or cancerous cells with low PD-L1 expression which comprises administering to the patient, as combination immunotherapy,
(a) an anti-semaphorin-4D (SEMA4D) antibody, or an antigen binding fragment thereof, and
(b) an immune checkpoint inhibitor,
wherein the tumor has, or said cancerous cells have, a total proportion score (TPS) ranging from <50% to <80% before the immune checkpoint inhibitor is administered.

### Claim 27 (depends on 26)

The method of claim 26, wherein TPS is <50.

### Claim 28 (depends on 26)

The method of claim 26, wherein said immune checkpoint inhibitor is an anti-PD-1 antibody, preferably pembrolizumab.

### Claim 29 (depends on 26)

The method of claim 26, wherein said anti-SEMA4D antibody is pepinemab.

### Claim 30 (depends on 26)

The method of claim 26, wherein said cancer is selected from the group consisting of locally advanced or recurrent or metastatic (in all of the following) head and neck cancer, non-small cell lung cancer, cervical cancer, urothelial carcinoma, esophogeal squamous cell carcinoma (ESCC), renal cell carcinoma, ovarian cancer, prostate cancer, bladder cancer, pancreatic cancer, gastrointestinal cancer, hepatocellular carcinoma, sarcoma, melanoma, triple negative breast cancer (TNBC), microsatellite instability/mismatch repair (MSI/MMR) deficient tumors and colorectal cancer.

### Claim 31 (depends on 21)

The method of claim 21, wherein said anti-SEMA4D antibody, or antigen binding fragment thereof, is administered at about 20 mg/kg.

### Claim 32 (depends on 21)

The method of claim 21, wherein said anti-SEMA4D antibody, or antigen binding fragment thereof, is administered intravenously every three weeks.

### Claim 33 (depends on 21)

The method of claim 21, wherein said immune checkpoint inhibitor is administered intravenously on the same cycle as said anti-SEMA4D antibody, or antigen binding fragment thereof.

### Claim 34 (depends on 21)

The method of claim 21, wherein said anti-SEMA4D antibody, or antigen binding fragment thereof, and said immune checkpoint inhibitor are administered to the subject sequentially or simultaneously, optionally wherein said anti-SEMA4D antibody, or antigen binding fragment thereof, and said immune checkpoint inhibitor are contained in the same pharmaceutical composition or separate pharmaceutical compositions.

### Claim 35 (depends on 21)

The method of claim 21, wherein said immune checkpoint inhibitor is an anti-PD-1 antibody.

### Claim 36 (depends on 35)

The method of claim 35, wherein said anti-PD-1 antibody is pembrolizumab.

### Claim 37 (depends on 21)

The method of claim 21, wherein said immune checkpoint inhibitor is pembrolizumab administered at a dosage of about 200 mg.
